Retatrutide, a GIP, GLP-1 and Glucagon Receptor Agonist, for People with Type 2 Diabetes: A Randomised, Double-Blind, Placebo and Active-Controlled, Parallel-Group, Phase 2 Trial Conducted in the USA, Rosenstock J
Tirzepatide B12 is initiated at a low dose to minimize gastrointestinal side effects, with gradual increases over time based on tolerance and response
Nausea was mentioned by 36.9% of users who described a side effect, followed by fatigue at 16.7%, vomiting at 16.3%, constipation at 15.3%, and diarrhea at 12.6%
Liposomal technology encapsulates nutrients in phospholipids, helping protect them from degradation during digestion
Current practice favors baseline B12 testing, then oral supplementation (cyanocobalamin or methylcobalamin) for low-normal or borderline levels, with escalation to IM injections if serum B12 declines despite oral therapy
Available from Accessed 29 Jul 2022 Chan JCN, Lim LL, Wareham NJ et al (2021) The Lancet Commission on diabetes: using data to transform diabetes care and patient lives
